Connect Biopharma Reports Second Quarter 2025 Financial Results and Provides Business Update
– Initiated Phase 2 Seabreeze STAT asthma and COPD studies evaluating rademikibart as an adjunct treatment for acute exacerbations –
Are there any upcoming conference presentations or investor events where further details on the trials will be disclosed?
What potential catalysts or risks could cause a material move in the CNXB stock price in the short‑term (e.g., trial results, FDA feedback, partnership announcements)?
How does the sentiment score of 20 reflect market perception, and what factors are driving that sentiment?
28 days ago